Description
BSE revokes the suspension in trading of equity shares of Vivimed Labs Ltd (Scrip Code: 532660), allowing resumption of trading on the exchange.
Summary
BSE has revoked the suspension in trading of equity shares of Vivimed Labs Limited (Scrip Code: 532660). This action allows the resumption of normal trading activities for the company’s equity shares on the BSE platform.
Key Points
- Company: Vivimed Labs Limited
- Scrip Code: 532660
- Action: Revocation of trading suspension
- Exchange: BSE (Bombay Stock Exchange)
- Circular Date: December 10, 2025
- Trading to resume with immediate effect
Regulatory Changes
The suspension previously imposed on Vivimed Labs Ltd equity shares has been lifted. Trading in the scrip is now permitted on the BSE platform, restoring normal market operations.
Compliance Requirements
- Market participants can resume trading in Vivimed Labs equity shares
- Standard trading rules and regulations apply
- Brokers and investors should update their systems to reflect the revocation
Important Dates
- Circular Date: December 10, 2025
- Effective Date: Immediate (from date of circular)
Impact Assessment
Market Impact: High - The revocation allows investors to buy and sell Vivimed Labs shares, restoring liquidity and price discovery for the scrip.
Investor Impact: High - Shareholders regain the ability to trade their holdings, which was previously restricted during the suspension period.
Operational Impact: Trading members and market participants can now accept and execute orders for Vivimed Labs equity shares through the BSE platform.
Impact Justification
Revocation of trading suspension directly impacts trading activity and investor access to Vivimed Labs equity shares, restoring normal market operations for the scrip